{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:16:24Z","timestamp":1790079384909,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000893","name":"Simons Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000893","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007653","name":"Jena University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014370","name":"Simons Foundation Autism Research Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ebr.2026.100897","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:27:43Z","timestamp":1789140463000},"page":"100897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Functional and pharmacological characterization of the SCN2A variant p.C258R with mixed gain and loss of function causing developmental and epileptic encephalopathy type 11"],"prefix":"10.1016","volume":"36","author":[{"given":"Alina","family":"K\u00f6ppel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Jamili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Stanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Brandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Leipold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H.","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebr.2026.100897_bb0005","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-3908","article-title":"Incidence and prevalence of childhood epilepsy: a nationwide cohort study","volume":"139","author":"Aaberg","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.ebr.2026.100897_bb0010","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1528-1167.2012.03631.x","article-title":"Sodium channels and the neurobiology of epilepsy","volume":"53","author":"Oliva","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2026.100897_bb0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/geno.1998.5735","article-title":"Evolution and diversity of mammalian sodium channel genes","volume":"57","author":"Plummer","year":"1999","journal-title":"Genomics"},{"key":"10.1016\/j.ebr.2026.100897_bb0020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.dib.2018.08.122","article-title":"Data on mutations and clinical features in SCN1A or SCN2A gene","volume":"22","author":"Kong","year":"2019","journal-title":"Data Brief"},{"key":"10.1016\/j.ebr.2026.100897_bb0025","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.0000000000001211","article-title":"The phenotypic spectrum of SCN8A encephalopathy","volume":"84","author":"Larsen","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ebr.2026.100897_bb0030","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/mp.2015.58","article-title":"Genes with de novo mutations are shared by four neuropsychiatric disorders discovered from NPdenovo database","volume":"21","author":"Li","year":"2016","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.ebr.2026.100897_bb0035","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/epi.13422","article-title":"SCN8A encephalopathy: research progress and prospects","volume":"57","author":"Meisler","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2026.100897_bb0040","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1172\/JCI25466","article-title":"Sodium channel mutations in epilepsy and other neurological disorders","volume":"115","author":"Meisler","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebr.2026.100897_bb0045","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.mp.4001241","article-title":"Sodium channels SCN1A, SCN2A and SCN3A in familial autism","volume":"8","author":"Weiss","year":"2003","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.ebr.2026.100897_bb0050","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tins.2018.03.011","article-title":"Progress in understanding and treating SCN2A-mediated disorders","volume":"41","author":"Sanders","year":"2018","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.ebr.2026.100897_bb0055","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/brain\/awx054","article-title":"Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders","volume":"140","author":"Wolff","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.ebr.2026.100897_bb0060","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.20029","article-title":"Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy","volume":"55","author":"Berkovic","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ebr.2026.100897_bb0065","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1528-1167.2007.01049.x","article-title":"SCN2A mutations and benign familial neonatal-infantile seizures: the phenotypic spectrum","volume":"48","author":"Herlenius","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2026.100897_bb0070","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0140-6736(02)09968-3","article-title":"Sodium-channel defects in benign familial neonatal-infantile seizures","volume":"360","author":"Heron","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ebr.2026.100897_bb0075","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.braindev.2011.09.016","article-title":"Clinical spectrum of SCN2A mutations","volume":"34","author":"Shi","year":"2012","journal-title":"Brain Dev"},{"key":"10.1016\/j.ebr.2026.100897_bb0080","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1073\/pnas.111065098","article-title":"A missense mutation of the Na+ channel \u03b1II subunit gene Nav1.2 in a patient with febrile and afebrile seizures causes channel dysfunction","volume":"98","author":"Sugawara","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ebr.2026.100897_bb0085","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000001926","article-title":"SCN2A encephalopathy: a major cause of epilepsy of infancy with migrating focal seizures","volume":"85","author":"Howell","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ebr.2026.100897_bb0090","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1523\/JNEUROSCI.3089-03.2004","article-title":"A nonsense mutation of the sodium channel gene SCN2A in a patient with intractable epilepsy and mental decline","volume":"24","author":"Kamiya","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.ebr.2026.100897_bb0095","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/WNL.0b013e3181f8812e","article-title":"SCN2A mutation associated with neonatal epilepsy, late-onset episodic ataxia, myoclonus, and pain","volume":"75","author":"Liao","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.ebr.2026.100897_bb0100","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.nbd.2012.05.017","article-title":"Compromised function in the Nav1.2 Dravet syndrome mutation R1312T","volume":"47","author":"Lossin","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.ebr.2026.100897_bb0105","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1212\/WNL.0b013e3182a43e57","article-title":"Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome","volume":"81","author":"Nakamura","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ebr.2026.100897_bb0110","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1212\/WNL.0b013e3181b9cebc","article-title":"De novo mutations of voltage-gated sodium channel alphaII gene SCN2A in intractable epilepsies","volume":"73","author":"Ogiwara","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ebr.2026.100897_bb0115","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.braindev.2009.08.009","article-title":"Missense mutation of the sodium channel gene SCN2A causes Dravet syndrome","volume":"31","author":"Shi","year":"2009","journal-title":"Brain Dev"},{"key":"10.1016\/j.ebr.2026.100897_bb0120","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1111\/epi.12137","article-title":"Whole genome sequencing identifies SCN2A mutation in monozygotic twins with Ohtahara syndrome and unique neuropathologic findings","volume":"54","author":"Touma","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2026.100897_bb0125","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/epi.12554","article-title":"Exome sequencing identifies a de novo SCN2A mutation in a patient with intractable seizures, severe intellectual disability, optic atrophy, muscular hypotonia, and brain abnormalities","volume":"55","author":"Baasch","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2026.100897_bb0130","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.biopsych.2017.01.009","article-title":"Opposing effects on NaV1.2 function underlie differences between SCN2A variants observed in individuals with autism Spectrum disorder or infantile seizures","volume":"82","author":"Ben-Shalom","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ebr.2026.100897_bb0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/YPG.0000000000000110","article-title":"Mutation screening of SCN2A in schizophrenia and identification of a novel loss-of-function mutation","volume":"26","author":"Carroll","year":"2016","journal-title":"Psychiatr Genet"},{"key":"10.1016\/j.ebr.2026.100897_bb0140","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/S0140-6736(12)61480-9","article-title":"Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study","volume":"380","author":"Rauch","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ebr.2026.100897_bb0145","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature10945","article-title":"De novo mutations revealed by whole-exome sequencing are strongly associated with autism","volume":"485","author":"Sanders","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ebr.2026.100897_bb0150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/YPG.0000000000000219","article-title":"Understanding the schizophrenia phenotype in the first patient with the full SCN2A phenotypic spectrum","volume":"29","author":"Suddaby","year":"2019","journal-title":"Psychiatr Genet"},{"key":"10.1016\/j.ebr.2026.100897_bb0155","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3389\/fphar.2020.01276","article-title":"Epilepsy-related voltage-gated sodium channelopathies: a review","volume":"11","author":"Menezes","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ebr.2026.100897_bb0160","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/sj.bjp.0701221","article-title":"Characterization of lamotrigine inhibition of Na+ channels in rat hippocampal neurones","volume":"121","author":"Kuo","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ebr.2026.100897_bb0165","doi-asserted-by":"crossref","DOI":"10.1085\/jgp.201912442","article-title":"Alternative splicing potentiates dysfunction of early-onset epileptic encephalopathy SCN2A variants","volume":"152","author":"Thompson","year":"2020","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.ebr.2026.100897_bb0170","first-page":"423","article-title":"Modulation of cloned skeletal muscle sodium channels by the scorpion toxins Lqh II, Lqh III, and Lqh alphaIT","volume":"439","author":"Chen","year":"2000","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.ebr.2026.100897_bb0175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0165-0270(97)00139-8","article-title":"Error estimates for results of nonstationary noise analysis derived with linear least squares methods","volume":"78","author":"Steffan","year":"1997","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.ebr.2026.100897_bb0180","unstructured":"Heinemann SH and Leipold E. (2011) Tools for studying peptide toxin modulation of voltage-gated sodium channels. In toxins and ion transfers (Barbier, ed.ds). SFET editions."},{"key":"10.1016\/j.ebr.2026.100897_bb0185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13073-021-00949-0","article-title":"Developmental dynamics of voltage-gated sodium channel isoform expression in the human and mouse brain","volume":"13","author":"Liang","year":"2021","journal-title":"Genome Med"},{"key":"10.1016\/j.ebr.2026.100897_bb0190","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/brain\/awq057","article-title":"Molecular correlates of age-dependent seizures in an inherited neonatal-infantile epilepsy","volume":"133","author":"Liao","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.ebr.2026.100897_bb0195","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1113\/jphysiol.2008.165787","article-title":"Cold-induced disruption of Na+ channel slow inactivation underlies paralysis in highly thermosensitive paramyotonia","volume":"587","author":"Carle","year":"2009","journal-title":"J Physiol"},{"key":"10.1016\/j.ebr.2026.100897_bb0200","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/0470846682.ch14","article-title":"Molecular mechanisms of gating and drug block of sodium channels","volume":"241","author":"Catterall","year":"2002","journal-title":"Novartis Found Symp"},{"key":"10.1016\/j.ebr.2026.100897_bb0205","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau2486","article-title":"Structure of the human voltage-gated sodium channel NaV1.4 in complex with \u03b21","volume":"362","author":"Pan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ebr.2026.100897_bb0210","doi-asserted-by":"crossref","first-page":"14646","DOI":"10.1073\/pnas.1211591109","article-title":"Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome","volume":"109","author":"Cheah","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ebr.2026.100897_bb0215","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000447526","article-title":"Phenotypic variability from benign infantile epilepsy to Ohtahara syndrome associated with a novel mutation in SCN2A","volume":"7","author":"Syrbe","year":"2016","journal-title":"Mol Syndromol"},{"key":"10.1016\/j.ebr.2026.100897_bb0220","doi-asserted-by":"crossref","first-page":"9270","DOI":"10.1073\/pnas.93.17.9270","article-title":"Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels","volume":"93","author":"Ragsdale","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ebr.2026.100897_bb0225","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/mol.110.064683","article-title":"Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore","volume":"78","author":"Lipkind","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ebr.2026.100897_bb0230","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(10)70059-4","article-title":"Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders","volume":"9","author":"Mantegazza","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebr.2026.100897_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.809951","article-title":"SCN2A-related epilepsy: the phenotypic spectrum, treatment and prognosis","volume":"15","author":"Zeng","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.ebr.2026.100897_bb0240","doi-asserted-by":"crossref","DOI":"10.1085\/jgp.202413658","article-title":"Drugs exhibit diverse binding modes and access routes in the Nav1.5 cardiac sodium channel pore","volume":"157","author":"Tao","year":"2025","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.ebr.2026.100897_bb0245","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.ebr.2026.100897_bb0250","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/BF00964003","article-title":"Interactions of some anaesthetic, convulsant, and anticonvulsant drugs at GABA-benzodiazepine receptor-ionophore complexes in rat brain synaptosomal membranes","volume":"8","author":"Skerritt","year":"1983","journal-title":"Neurochem Res"},{"key":"10.1016\/j.ebr.2026.100897_bb0255","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/S0028-3908(00)00051-4","article-title":"The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro","volume":"39","author":"Cunningham","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ebr.2026.100897_bb0260","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0014-2999(96)00265-8","article-title":"Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications","volume":"307","author":"Stefani","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ebr.2026.100897_bb0265","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0304-3940(97)00543-0","article-title":"Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells","volume":"231","author":"Zona","year":"1997","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.ebr.2026.100897_bb0270","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0022-3565(24)38047-4","article-title":"Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate","volume":"288","author":"Taverna","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ebr.2026.100897_bb0275","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1528-1157.1994.tb02459.x","article-title":"Topiramate: preclinical evaluation of structurally novel anticonvulsant","volume":"35","author":"Shank","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2026.100897_bb0280","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0920-1211(97)00045-4","article-title":"Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold","volume":"28","author":"White","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2026.100897_bb0285","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1157.2000.tb02164.x","article-title":"Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons","volume":"41","author":"Gibbs","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2026.100897_bb0290","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1528-1157.2000.tb02169.x","article-title":"Topiramate as an inhibitor of carbonic anhydrase isoenzymes","volume":"41","author":"Dodgson","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2026.100897_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150271","article-title":"Structural insights into the allosteric effects of the antiepileptic drug topiramate on the CaV2.3 channel","volume":"725","author":"Gao","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ebr.2026.100897_bb0300","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1528-1157.2000.tb02166.x","article-title":"Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture","volume":"41","author":"McLean","year":"2000","journal-title":"Epilepsia"}],"container-title":["Epilepsy & Behavior Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986426000511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986426000511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:52:11Z","timestamp":1790077931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589986426000511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":60,"alternative-id":["S2589986426000511"],"URL":"https:\/\/doi.org\/10.1016\/j.ebr.2026.100897","relation":{},"ISSN":["2589-9864"],"issn-type":[{"value":"2589-9864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional and pharmacological characterization of the SCN2A variant p.C258R with mixed gain and loss of function causing developmental and epileptic encephalopathy type 11","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebr.2026.100897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100897"}}